Advancing Clinical-Grade TIL Therapy Manufacturing

Advances in adoptive cell therapy have positioned tumor-infiltrating lymphocytes (TILs) as a promising approach for treating solid tumors. Yet, the path from tumor sample to effective therapy remains complex, with manufacturing variability and scalability posing ongoing challenges. A more controlled, reproducible process is essential to deliver consistent clinical outcomes. A standardized, automated approach to generating tumor-reactive T cells (TRTs) offers a way forward, helping streamline workflows, reduce manual intervention, and improve reliability across production. Exploring how automation can support TIL expansion and enrichment sheds light on the next phase of cell therapy development.

Gain practical insights into building a more efficient TIL manufacturing strategy.